Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (8034)	11/16/2001 1:49:24 PM
From: Joe Krupa	Respond to of 14101

Wolf "Now the 40,000 will move to the 3.50 to put the lid at the long term support as soon as they move safely just below." I bet your correct. Down to $3.37 for low so far, and no significant stops in - that surprised me. joe

To: Montana Wildhack who wrote (8034)	11/16/2001 2:02:14 PM
From: E. T.	Respond to of 14101

I'd like to see more volume at these prices.eom

To: Montana Wildhack who wrote (8034)	11/16/2001 2:09:03 PM
From: freedom-35	Read Replies (1) \| Respond to of 14101

Hmmm, yes. Looks like another 52 week low. How encouraging! I understand RK strategies when she won't accept Pennsaid to be a 2nd line therapy, but it seems to me that this is breaking us. I see a clinically proven product just waiting for a long string of approvals (HC, FDA, more widespread in the EU) that may be or have been delayed due to the Company's marketing strategy. More importantly, I see a transdermal delivery method which has huge potential to be integrated with other proven active ingredients and capture large parts of markets other than OA. On top of that, there's the WF-10 potential. In the UK market, Pennsaid has been available for 8 months with zero indication to shareholders on sales, shipments or revenues. Seems even the good news has turned into no news. I understand that Pennsaid is the flagship product for DMX now and that RK wants it marketed as such. It's safe and effective, particularly when compared to its competition. I agree, it should be a first line treatment. But ships are best tested when put into water. Sitting on the dock proves nothing. Long and short of it; the company has potential in its products and it's disappointing to see it effectively driving its share price and credibility down by demanding too much rather than chosing to add to it's revenue streams. Whew! That feels better! Thanks for listening! F-35